Investor Presentation First Nine Months of 2023
153
Investor presentation
First nine months of 2023
Novo NordiskⓇ
2022 statement of ESG performance
Environmental
performance
Resources
Energy consumption for operations (1,000 GJ)
Share of renewable power for production sites
Water consumption for production sites (1,000 m³)
Breaches of environmental regulatory limit values
Emissions and waste
Scope 1 emissions (1,000 tonnes)
2022
2021
2020
3,677
3,387
3,191
100%
100%
100%
3,918
3,488
3,368
75
12
15
76
77
75
Scope 2 emissions (1,000 tonnes)
16
16
15
Scope 3 emissions (1,000 tonnes)1
2,041
NA
NA
Waste from production sites (tonnes)
213,505
180,806
140,783
Patients
Patients reached with Novo Nordisk's Diabetes care products (estimate in millions)
36.3
34.6
- Hereof reached via the Novo Nordisk Access to Insulin Commitment (estimate in millions)²
1.8
1.7
32.8
3.2
- Hereof children reached through Changing Diabetes® in Children (cumulative)
People & employees
41,033
31,846
28,296
Employees (total)
55,185
48,478
45,323
Social
performance
Employee turnover
Sustainable Employer Score³
Gender in leadership positions (ratio men:women)
Gender in senior leadership positions (ratio men:women)
Gender in the Board of Directors (ratio men:women)
Societies
8.2%
11.0%
7.9%
85%
84%
N/A
Frequency of occupational accidents (number per million working hours)
1.5
1.3
1.3
56:44
57:43
59:41
61:39
64:36
65:35
54:46
67:33
62:38
Total tax contribution (DKK million)
36,003
32,593
26,376
Donations and other contributions (DKK million)
126
92
158
Change in average list price across US product portfolio (% change to previous year)
2.4%
1.6%
2.3%
Change in average net price across US product portfolio (% change to previous year)
Change in average list price across US insulin portfolio (% change to previous year)
Change in average net price across US insulin portfolio (% change to previous year)
Governance processes
-12.7%
-12.3%
0.0%
0.0%
-19.5%
-10.9%
-16.9%
0.5%
-26.9%
Governance
Performance
Business ethics reviews
Employees trained in business ethics
Supplier audits
Product recalls
Failed inspections
Values and trust
Facilitations of the Novo Nordisk Way
35
37
32
99%
98%
99%
294
253
177
3
1
0
0
0
0
36
Company reputation (scale 0-100)4
Animals purchased for research
82.3
79,750
34
82.6
47,879
26
N/A
50,036
1.2022 is the first year of full Scope 3 emissions' disclosure, which in 2020 and 2019 was limited to business flights and product distribution. 2. In 2020, the ceiling price was lowered from USD 4 to USD 3 which affects the comparability of 2021 and prior years 3. In 2021, the engagement survey was entirely redesigned to support Novo Nordisk's
strategic goals. As a result, comparison to previous surveys is not appropriate. 4. In 2021, Company reputation replaced Company trust in order to capture more dimensions of how Novo Nordisk is perceived by external stakeholders.View entire presentation